Understanding and circumventing resistance to anticancer monoclonal antibodies.
With the widespread use of therapeutic monoclonal antibodies in the treatment of patients with cancer, resistance to these agents has become a major issue. Preclinical models of drug action or resistance have contributed to unravel the main mechanisms of resistance, involving both tumor-associated and host related factors. However our understanding of how a monoclonal antibody destroys cancer cells in a patient and why it one day stops being effective are still far from being complete. This review focuses on the available data on mechanisms of action and resistance to rituximab and includes some additional information for other monoclonal antibodies. Innovative approaches designed to overcome resistance, such as combination immunotherapy, costimulation with cytokines or growth factors are presented.
Reslan
Lina
L
Inserm U590, Lyon, France.
Dalle
Stéphane
S
Dumontet
Charles
C
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects* / Q000276:immunology; D016207:Cytokines / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000276:immunology*; D004359:Drug Therapy, Combination; D006801:Humans; D007116:Immunization, Passive; D036341:Intercellular Signaling Peptides and Proteins / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D016207:Cytokines; D036341:Intercellular Signaling Peptides and Proteins; D000069283:Rituximab